Hydroxychloroquine

Early treatment with mycophenolate mofetil can reduce subsequent risks for severe flares and lupus nephritis in newly diagnosed systemic lupus erythematosus, according to data published in JAMA Network Open.

May is Lupus Awareness Month, a time to raise awareness and educate the public on the physical, emotional and financial impact of lupus.

Hydroxychloroquine use for systemic lupus erythematosus or rheumatoid arthritis in the first trimester of pregnancy does not significantly increase the risk for major congenital malformations, according to data published in Rheumatology.

SAN DIEGO — Patients with lupus who maintained hydroxychloroquine blood levels of 750 ng/ml to 1,200 ng/ml exhibited 71% to 90% lower risk for high lupus disease activity, according to data presented at ACR Convergence 2023.

SAN DIEGO — Improving hydroxychloroquine use and reducing glucocorticoid exposure are among the top priorities of the Healthy People with Lupus 2030 initiative, which aims to address care disparities, said a speaker at ACR Convergence 2023.

SAN DIEGO — Patients with rheumatoid arthritis who receive hydroxychloroquine demonstrate a lower risk for nonalcoholic fatty liver disease, according to data presented at ACR Convergence 2023.

Although the annual retinopathy screening rate in patients with lupus receiving hydroxychloroquine has increased from 3.5% in 2006 to 22.5% in 2019, more work is needed to raise awareness, according to data from a South Korean study.